Procalcitonin Testing Not Impacting Antibiotic Rx for COPD

This article originally appeared here.
Share this content:
Procalcitonin Testing Not Impacting Antibiotic Rx for COPD
Procalcitonin Testing Not Impacting Antibiotic Rx for COPD

FRIDAY, Aug. 18, 2017 (HealthDay News) -- Hospital adoption of procalcitonin (PCT) testing has had little impact on antibiotic prescribing for chronic obstructive pulmonary disease (COPD) exacerbations, according to a study published online Aug. 10 in the Annals of the American Thoracic Society.

Peter K. Lindenauer, M.D., from Baystate Medical Center in Springfield, Mass., determined the impact of PCT testing on antibiotic treatment of patients hospitalized for exacerbations of COPD in routine practice. The authors evaluated data from 505 hospitals (2009 to 2011 and 2013 to 2014).

The researchers found that of 203,177 patients hospitalized for COPD exacerbation in 2013 to 2014, nearly nine out of 10 were treated with antibiotics, while hospital PCT testing rates ranged from 0 to 83 percent. There was a weak negative association between the rate of PCT testing and risk-adjusted rates of antibiotic initiation (P = 0.005), with each 10 point increase in the percentage of patients undergoing PCT testing associated with a 0.7 percent decline in risk-adjusted antibiotic use (P = 0.001). There was not a significant change in antibiotic treatment rates or duration of therapy between hospitals that had adopted PCT testing compared to those that had not, when comparing treatment patterns between 2009 to 2011 and 2013 to 2014.

"As currently implemented, PCT testing appears to have had little impact on decisions to initiate antibiotic therapy or on duration of treatment for COPD exacerbations," the authors write.

Abstract
Full Text (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »

Drug Lookup

Browse drugs by: BrandGenericDisease

Trending Activities

All Professions


Sign up for myCME e-newsletters


More in Home

FDA OKs Nucala for Eosinophilic Granulomatosis With Polyangiitis

FDA OKs Nucala for Eosinophilic Granulomatosis With Polyangiitis

First drug to be approved for rare autoimmune disease that leads to vasculitis

Findings Support Individualized Glycemic Control in T2DM

Findings Support Individualized Glycemic Control in T2DM

Approach saved $13,547/patient vs uniform intensive control, with lower medication costs

Atherosclerosis ID'd in Many Without CV Risk Factors

Atherosclerosis ID'd in Many Without CV Risk Factors

LDL-C independently associated with the presence and extent of atherosclerosis

is free, fast, and customized just for you!

Already a member?

Sign In Now »